Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: HMN021
MIFTS: 47

Human T-Cell Leukemia Virus Type 1

Categories: Blood diseases, Cancer diseases, Immune diseases, Infectious diseases, Rare diseases, Skin diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Human T-Cell Leukemia Virus Type 1

About this section

MalaCards integrated aliases for Human T-Cell Leukemia Virus Type 1:

Name: Human T-Cell Leukemia Virus Type 1 52
Human T Lymphotropic Virus Type 1 52
Htlv-1 52

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases Infectious diseases
Anatomical: Immune diseases Skin diseases Blood diseases
See all MalaCards categories (disease lists)


Sources

Summaries for Human T-Cell Leukemia Virus Type 1

About this section
NIH Rare Diseases : 52 Human T-cell leukemia virus , type 1 (HTLV-1) is a retroviral infection that affect the T cells (a type of white blood cell ). Although this virus generally causes no signs or symptoms, some affected people may later develop adult T-cell leukemia (ATL) , HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP) or other medical conditions. HTLV-1 is spread by blood transfusions, sexual contact and sharing needles. It can also be spread from mother to child during birth or breast-feeding. There is no cure or treatment for HTLV-1 and it is considered a lifelong condition; however, most (95%) infected people remain asymptomatic (show no symptoms) throughout life.

MalaCards based summary : Human T-Cell Leukemia Virus Type 1, also known as human t lymphotropic virus type 1, is related to human t-cell leukemia virus type 2 and t-cell lymphoblastic leukemia/lymphoma. An important gene associated with Human T-Cell Leukemia Virus Type 1 is CRTC2 (CREB Regulated Transcription Coactivator 2), and among its related pathways/superpathways are Toll-like Receptor Signaling Pathway and G-Beta Gamma Signaling. The drugs Valproic acid and Zidovudine have been mentioned in the context of this disorder. Affiliated tissues include t cells, breast and bone, and related phenotypes are Increased TP53 mRNA expression and Increased virus production

Wikipedia : 74 Human T-cell lymphotropic virus type 1 or human T-lymphotropic virus type 1 (HTLV-I), also called the... more...

Sources

Related Diseases for Human T-Cell Leukemia Virus Type 1

About this section

Diseases in the Adult T-Cell Leukemia family:

Human T-Cell Leukemia Virus Type 1 Human T-Cell Leukemia Virus Type 2
Human T-Cell Leukemia Virus Type 3 Leukemia, T-Cell, Chronic

Diseases related to Human T-Cell Leukemia Virus Type 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 393)
# Related Disease Score Top Affiliating Genes
1 human t-cell leukemia virus type 2 29.1 NFKB1 EP300 CREBBP CREB1 CNTN2
2 t-cell lymphoblastic leukemia/lymphoma 29.1 NFKB1 JUND JUN GLI2 EP300 CREBBP
3 infective dermatitis associated with htlv-1 12.4
4 htlv-1 associated myelopathy/tropical spastic paraparesis 12.1
5 adult t-cell leukemia 12.0
6 retrovirus-associated myelopathy 11.6
7 intermediate uveitis 11.5
8 leukemia, t-cell, chronic 11.4
9 pars planitis 11.2
10 myelopathy, htlv-1-associated 10.9
11 spastic paraparesis 10.9
12 tropical spastic paraparesis 10.9
13 human immunodeficiency virus type 1 10.7
14 leukemia 10.6
15 t-cell adult acute lymphocytic leukemia 10.6
16 strongyloidiasis 10.5
17 lymphoma 10.5
18 stomatitis 10.5
19 uveitis 10.4
20 polymyositis 10.4
21 dermatitis 10.3
22 myopathy 10.3
23 paraplegia 10.3
24 leukemia, chronic lymphocytic 10.3
25 retinoblastoma 10.3
26 immune deficiency disease 10.3
27 osteogenic sarcoma 10.3
28 hepatitis c virus 10.3
29 vaccinia 10.3
30 familial retinoblastoma 10.3
31 severe combined immunodeficiency 10.3
32 mycosis fungoides 10.3
33 myositis 10.3
34 autoimmune disease 10.3
35 neurogenic bladder 10.2
36 meningitis 10.2
37 hypercalcemia, infantile, 1 10.2
38 leukemia, acute lymphoblastic 10.2
39 helix syndrome 10.2
40 diphtheria 10.2
41 arthropathy 10.2
42 b-cell lymphoma 10.2
43 herpes simplex 10.2
44 acute liver failure 10.2
45 neuroretinitis 10.2
46 retinal vasculitis 10.2
47 retinitis 10.2
48 bile duct mucoepidermoid carcinoma 10.2 CRTC1 CREB1
49 clear cell hidradenoma 10.2 CRTC3 CRTC1
50 cutaneous t cell lymphoma 10.2

Graphical network of the top 20 diseases related to Human T-Cell Leukemia Virus Type 1:



Diseases related to Human T-Cell Leukemia Virus Type 1
Sources

Symptoms & Phenotypes for Human T-Cell Leukemia Virus Type 1

About this section

GenomeRNAi Phenotypes related to Human T-Cell Leukemia Virus Type 1 according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased TP53 mRNA expression GR00389-S-5 8.96 JUN NFKB1
2 Increased virus production GR00378-A 8.8 CREB1 EP300 JUND

MGI Mouse Phenotypes related to Human T-Cell Leukemia Virus Type 1:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10 CDKN1A CREB1 CREBBP CRTC1 CRTC2 CRTC3
2 endocrine/exocrine gland MP:0005379 9.97 CDKN1A CREB1 CREBBP CRTC1 EP300 GLI2
3 adipose tissue MP:0005375 9.85 CDKN1A CREBBP CRTC1 CRTC2 CRTC3 JUND
4 liver/biliary system MP:0005370 9.7 CDKN1A CREBBP CRTC2 CRTC3 JUN JUND
5 muscle MP:0005369 9.56 CDKN1A CREB1 CREBBP CRTC3 EP300 GLI2
6 respiratory system MP:0005388 9.23 CDKN1A CREB1 CREBBP EP300 GLI2 JUN
Sources

Drugs & Therapeutics for Human T-Cell Leukemia Virus Type 1

About this section

Drugs for Human T-Cell Leukemia Virus Type 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 109)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
2
Zidovudine Approved Phase 4 30516-87-1 35370
3
Peginterferon alfa-2b Approved Phase 4 99210-65-8, 215647-85-1
4 Anti-Infective Agents Phase 4
5 Antiviral Agents Phase 4
6 Anti-HIV Agents Phase 4
7 Anti-Retroviral Agents Phase 4
8 Immunologic Factors Phase 4
9 Anticonvulsants Phase 4
10 Neurotransmitter Agents Phase 4
11 interferons Phase 4
12 Psychotropic Drugs Phase 4
13 Reverse Transcriptase Inhibitors Phase 4
14 Antimetabolites Phase 4
15 Interferon-alpha Phase 4
16 Interferon alpha-2 Phase 4
17
Lamivudine Approved, Investigational Phase 2, Phase 3 134678-17-4 60825
18
Lopinavir Approved Phase 2, Phase 3 192725-17-0 92727
19
Ritonavir Approved, Investigational Phase 2, Phase 3 155213-67-5 392622
20
Pentoxifylline Approved, Investigational Phase 3 6493-05-6 4740
21
Ivermectin Approved, Investigational, Vet_approved Phase 3 70288-86-7 6474909
22
Mogamulizumab Approved, Investigational Phase 3 1159266-37-1
23 Integrase Inhibitors Phase 2, Phase 3
24 HIV Integrase Inhibitors Phase 2, Phase 3
25 Raltegravir Potassium Phase 2, Phase 3
26 Cytochrome P-450 Enzyme Inhibitors Phase 2, Phase 3
27
protease inhibitors Phase 2, Phase 3
28 HIV Protease Inhibitors Phase 2, Phase 3
29 Cytochrome P-450 CYP3A Inhibitors Phase 2, Phase 3
30 Phosphodiesterase Inhibitors Phase 3
31 Antioxidants Phase 3
32 Platelet Aggregation Inhibitors Phase 3
33 Vasodilator Agents Phase 3
34 Protective Agents Phase 3
35 Radiation-Protective Agents Phase 3
36 Antiparasitic Agents Phase 3
37
Triamcinolone Approved, Vet_approved Phase 1, Phase 2 124-94-7 31307
38
Cyclophosphamide Approved, Investigational Phase 1, Phase 2 50-18-0, 6055-19-2 2907
39
Vincristine Approved, Investigational Phase 1, Phase 2 57-22-7, 2068-78-2 5978
40
Doxorubicin Approved, Investigational Phase 1, Phase 2 23214-92-8 31703
41
Prednisone Approved, Vet_approved Phase 1, Phase 2 53-03-2 5865
42
Lenalidomide Approved Phase 2 191732-72-6 216326
43
Etoposide Approved Phase 1, Phase 2 33419-42-0 36462
44
Bortezomib Approved, Investigational Phase 1, Phase 2 179324-69-7 387447 93860
45
Interferon beta-1a Approved, Investigational Phase 2 145258-61-3 6438354
46
nivolumab Approved Phase 2 946414-94-4
47
Lenograstim Approved, Investigational Phase 2 135968-09-1
48
Gemcitabine Approved Phase 1, Phase 2 95058-81-4 60750
49
leucovorin Approved Phase 1, Phase 2 58-05-9 6006 143
50
Methylcobalamin Approved, Investigational Phase 1, Phase 2 13422-55-4

Interventional clinical trials:

(show top 50) (show all 51)
# Name Status NCT ID Phase Drugs
1 Prospective Study of the Molecular Characteristics of Sensitive and Resistant Disease in Patients With HTLV-I Associated Adult T Cell Leukemia Treated With Zidovudine (AZT) Plus Interferon Alpha-2b Terminated NCT00854581 Phase 4 Valproic Acid;Zidovudine
2 Open-Label, Exploratory Study of the Efficacy and Safety of Tamibarotene(AM80H) for HTLV-1 Associated Myelopathy/ Tropical Spastic Paraparesis (HAM/TSP) Unknown status NCT01343355 Phase 2, Phase 3 Tamibarotene
3 Evaluation of the Use of Antiretroviral Regimens Containing Raltegravir for Prophylaxis of Mother-to-child-transmission of HIV Infection in Pregnant Women Presenting With Detectable Viral Load After 32 Weeks of Gestation: a Pilot Study Unknown status NCT01854762 Phase 2, Phase 3 Raltegravir;Lopinavir/Ritonavir
4 Effectiveness of Pentoxifylline in Attenuating Neurological Disease Associated With HTLV-1 and Negative Modulator of Pathological Immune Response. Completed NCT01472263 Phase 3 Pentoxifylline;Placebo
5 Study Of Valproic Acid To Treat TSP/HAM Patients In Sao Paulo, Brazil Completed NCT00681980 Phase 3 Valproic acid;costicosteroids;valproid acid plus corticosteroids
6 A Comparative Study of Two Regimens of Ivermectin for the Treatment of Strongyloides Stercoralis Infection Recruiting NCT03605758 Phase 3 Ivermectin
7 A Phase 3 Multicenter, Randomized, Double-Blind and Placebo-Controlled Study, and Open Study of KW-0761 in Patients With HTLV-1 Associated Myelopathy (HAM) Active, not recruiting NCT03191526 Phase 3 KW-0761 0.3 mg/kg IV;Placebo (saline)
8 Randomized Study of Romidepsin Versus the Combination of Romidepsin Plus Pralatrexate in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) Withdrawn NCT03355768 Phase 3 Romidepsin;Pralatrexate
9 Phase II Study of Alemtuzumab in Patients With Advanced Mycosis Fungoides/Sezary Syndrome Unknown status NCT00157274 Phase 2 alemtuzumab
10 A Phase I/II Study of the Efficacy and Toxicity of Humanized Anti-Tac (Zenapax(Trademark)) in the Therapy of Tac-Expressing Adult T-Cell Leukemia Completed NCT00001941 Phase 1, Phase 2
11 Phase I/II Trial of Dose-Adjusted EPOCH Chemotherapy With Bortezomib Combined With Integrase Inhibitor Therapy for HTLV-1 Associated T-Cell Leukemia Lymphoma Completed NCT01000285 Phase 1, Phase 2 Bortezomib;Etoposide;Vincristine;Doxorubicin;Prednisone;Cyclophosphamide;Raltegravir
12 Combined Virological and Immunological Evaluation of Treatment of Patients With Early HTLV-1-Associated Myelopathy With Recombinant Human Interferon Beta-1a Completed NCT00001785 Phase 2 Recombinant human interferon beta-1a
13 Phase II Trial of Nivolumab for HTLV-Associated Adult T Cell Leukemia/Lymphoma Completed NCT02631746 Phase 2
14 A Phase II Study of Lenalidomide in Patients With Relapsed or Refractory HTLV-1 Associated Adult T Cell Leukemia/Lymphoma Completed NCT01274533 Phase 2 Lenalidomide
15 Phase II Trial Of Induction Therapy With EPOCH Chemotherapy And Maintenance Therapy With Combivir/Interferon ALPHA-2a For HTLV-1 Associated T-Cell Non-Hodgkin's Lymphoma Completed NCT00041327 Phase 2 Etoposide;cyclophosphamide;doxorubicin hydrochloride;lamivudine;prednisone;vincristine sulfate;zidovudine
16 Phase II Study of the Efficacy and Toxicity of Campath-1H in the Therapy of Adult T-Cell Leukemia Completed NCT00061048 Phase 2
17 A Phase 1/2a Open-label Study of Pralatrexate and Gemcitabine With Vitamin B12 and Folic Acid Supplementation in Patients With Relapsed or Refractory Lymphoproliferative Malignancies Completed NCT00481871 Phase 1, Phase 2 Pralatrexate Injection;Gemcitabine Hydrochloride
18 Phase II Study of Therapy With IMTOX-25 in Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma Completed NCT01378871 Phase 2 IMTOX-25
19 Most Closely HLA Matched Allogeneic Virus Specific Cytotoxic T-Lymphocytes (CTL) to Treat Persistent Reactivation Or Infection With Adenovirus, CMV and EBV After Hemopoietic Stem Cell Transplantation (HSCT) Completed NCT00711035 Phase 1, Phase 2
20 Phase II Trial Evaluating the Safety and Efficacy of Ruxolitinib in Patients With Smoldering and Chronic Adult T-cell Leukemia (ATL) Recruiting NCT01712659 Phase 2 Ruxolitinib;ruxolitinib
21 Phase II Trial of LMB-2, Fludarabine and Cyclophosphamide for Adult T-Cell Leukemia Active, not recruiting NCT00924170 Phase 1, Phase 2 LMB-2;Fludarabine;Cyclophosphamide
22 Extended Dose - Total Body Irradiation Followed By Allogeneic Stem Cell Transplantation For The Treatment Of Refractory Acute Leukemia And Advanced Myelodysplastic Syndrome Suspended NCT01709396 Phase 2
23 Phase II Trial to Assess Effect of Raltegravir on HTLV-1 Proviral Load Withdrawn NCT01620736 Phase 2 Raltegravir
24 Immunotherapy of Natural Killer in HTLV-1 Associated Myelopathy Unknown status NCT02961712 Phase 1
25 A Randomized, Placebo-Controlled Study to Assess the Efficacy of Propantheline for the Treatment of Overactive Bladder Unknown status NCT01640002 Phase 1 Propantheline Bromide;Placebo
26 Human OK99 Allogeneic Stem Cell Transplantation for Patients With Severe Parkinson's Disease Unknown status NCT02780895 Phase 1 Human Stem Cells
27 Phase I Study of HTLV-I-Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP) Using the Humanized MiK-Beta-1 Monoclonal Antibody Directed Toward the IL-2L-15R-Beta; Subunit (CD122) That Blocks IL-15 Action Completed NCT00076843 Phase 1 Hu MiK-Beta-1
28 A Phase I, Multicenter, Open-label, Dose-escalation Study to Assess the Safety of Lenalidomide in Patients With Advanced Adult T-cell Leukemia-lymphoma and Peripheral T-cell Lymphoma Completed NCT01169298 Phase 1 Lenalidomide
29 A Phase I Study Of Subcutaneous Recombinant Human IL-15 (S.C.rhIL-15) and Alemtuzumab for Patients With Refractory or Relapsed Chronic and Acute Adult T-Cell Leukemia (ATL) Recruiting NCT02689453 Phase 1
30 A Phase 1 Study of Lenalidomide in Combination With EPOCH Chemotherapy for HTLV-Associated Adult T-Cell Leukemia-Lymphoma (ATLL) Not yet recruiting NCT04301076 Phase 1 Cyclophosphamide;Doxorubicin Hydrochloride;Etoposide;Lenalidomide;Prednisone;Vincristine Sulfate
31 Biomarker Discovery In Children With Autism Plus Familial Autoimmune History Completed NCT01541033
32 Effects of Physiotherapy in the Treatment of Neurogenic Bladder in Patients Infected With Human T-Lymphotropic Virus 1 Completed NCT01651819
33 Influence of IL28B Genetic Variation on the Phenotype Infection of HTLV-1 Completed NCT01754311
34 Pilot Study of Raltegravir, an Integrase Inhibitor, in Human T-Cell Lymphotrophic Virus-1(HTLV-1) Associated Myelopathy, Tropical Spastic Paraparesis (HAM/TSP) Completed NCT01867320 Early Phase 1 Raltegravir
35 Sensorimotor Exercises in Virtual Reality Platform and Balance in Individuals With Human T-lymphotropic Virus Completed NCT02877030
36 Effect of Raltegravir in Patients With Myelopathy/Tropical Spastic Paraparesis Associated With Infection by Human T-Lymphotropic Virus 1 (HTLV-1). Pilot Study Completed NCT02655471 Early Phase 1 "Raltegravir" and "Zidovudine"
37 Signaling in Tumorigenesis and Immunity Completed NCT01520246
38 MRI Investigation Of The CNS In HTLV-1 Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP) Completed NCT00034723
39 A Study of Familial and Genetic Aspects of Adult T-Cell Leukemia/Lymphoma, Tropical Spastic Paraparesis and Infective Dermatitis in Jamaica Completed NCT00340821
40 Epidemic History and Iatrogenic Transmission of Blood-borne Viruses Completed NCT02439918
41 Prediagnostic Markers of Adult T-Cell Leukemia/Lymphoma Among Carriers of Human T-Lymphoma Virus Type I: A Collaborative Study Completed NCT00339638
42 Analysis of Clinical and Immunological Characteristics, as Well as Pathophysiological Mechanisms in a French Cohort of Patients With Idiopathic CD4 Lymphocytopenia Completed NCT02113930
43 Natural History of HTVL-I: A Cross-Sectional Study of a Cohort of Blood Donors in Jamaica Completed NCT00339807
44 Late Effects of Treatment in Survivors of Pediatric Sarcomas Completed NCT00006515
45 Immuno-Virological Evaluation of Human T Cell Leukemia Virus Type-1 Associated Myelopathy (HAM/TSP) Recruiting NCT00001778
46 Collection of Blood, Bone Marrow and Tissue Samples for the Investigation of the Human Immune Response, Lymphoma Biology and HTLV-1 Infection Recruiting NCT00001582
47 Collection of Blood, Bone Marrow, Tumor, or Tissue Samples From Patients With HIV Infection, KSHV Infection, Viral-Related Pre-Malignant Lesions, and/or Cancer Recruiting NCT00006518
48 Electromiography Study in the Respiratory Muscle Training in Human Lymphotropic Virus Type 1 Recruiting NCT03829709
49 Epidemiological and Molecular Aspects of the Interspecies Transmission of Foamy Viruses From Monkeys to Humans: A Model of the Early Stages of Viral Emergence. Recruiting NCT03225794
50 Autologous Ovarian Tissue Transplantation Recruiting NCT03496636

Search NIH Clinical Center for Human T-Cell Leukemia Virus Type 1

Sources

Genetic Tests for Human T-Cell Leukemia Virus Type 1

About this section
Sources

Anatomical Context for Human T-Cell Leukemia Virus Type 1

About this section

MalaCards organs/tissues related to Human T-Cell Leukemia Virus Type 1:

40
T Cells, Breast, Bone, Bone Marrow, B Cells, Lung, Brain
Sources

Publications for Human T-Cell Leukemia Virus Type 1

About this section

Articles related to Human T-Cell Leukemia Virus Type 1:

(show top 50) (show all 2098)
# Title Authors PMID Year
1
Multiple recombinant events in human T-cell Leukemia virus Type 1: complete sequences of recombinant African strains. 61
32249692 2020
2
High-yield production in E. coli and characterization of full-length functional p13II protein from human T-cell leukemia virus type 1. 61
32360379 2020
3
Human T cell lymphotropic virus type-1 associated lymphoma presenting as an intramuscular mass of the calf. 61
32076761 2020
4
Structural basis of host protein hijacking in human T-cell leukemia virus integration. 61
32561747 2020
5
HTLV-1 induces T cell malignancy and inflammation by viral antisense factor-mediated modulation of the cytokine signaling. 61
32471947 2020
6
Rapid and label-free electrochemical DNA biosensor based on a facile one-step electrochemical synthesis of rGO-Ppy-(L-Cys)- AuNPs nanocomposite for the HTLV-1 oligonucleotide detection. 61
32542764 2020
7
Hospital admissions in individuals with HTLV-1 infection in Spain. 61
32073449 2020
8
Immunophenotypic analysis of cerebrospinal fluid reveals concurrent development of ATL in the CNS of a HAM/TSP patient. 61
31930455 2020
9
Phylogenetic and phylodynamic study of Human T-cell lymphotropic virus Type 1 (HTLV-1) in Iran. 61
32561293 2020
10
Frequent horizontal and mother-to-child transmission may contribute to high prevalence of STLV-1 infection in Japanese macaques. 61
32576215 2020
11
HTLV-1 seropositive patients with lung cancer treated with PD-1 inhibitors. 61
32557883 2020
12
Evolution of retrovirus-infected premalignant T-cell clones prior to adult T-cell leukemia/lymphoma diagnosis. 61
32160278 2020
13
Long-term prognosis in kidney transplant recipients with human T-cell leukemia virus type 1 infection. 61
32386274 2020
14
The reasons to include the serology of human T-lymphotropic virus types 1 and 2 (HTLV-1 and HTLV-2) in the clinical follow-up of patients with viral hepatitis B and C in Brazil. 61
32453768 2020
15
Clinical features and human T-cell leukemia virus type-1 (HTLV-1) proviral load in HTLV-1-positive patients with rheumatoid arthritis: Baseline data in a single center cohort study. 61
30938551 2020
16
Activation of PERK-ATF4-CHOP pathway as a novel therapeutic approach for efficient elimination of HTLV-1-infected cells. 61
32369565 2020
17
Functional properties and sequence variation of HTLV-1 p13. 61
32398094 2020
18
Adult T-cell leukemia/lymphoma incidence rate in French Guiana: a prospective cohort of women infected with HTLV-1. 61
32396612 2020
19
Inefficient Tax-Specific T-Cell Responses in Mice after Syngeneic Transplantation with tax-Transgenic Mouse-Derived Adult T-Cell Leukemia Cells. 61
32009059 2020
20
cDNA-Based Mutation Screening Using a Combination of High-Resolution Melting Curve and Fragment Analysis Facilitates Efficient CCR4 Mutation Analysis in Adult T-Cell Leukemia/Lymphoma. 61
32367127 2020
21
Associations of Viral Seroreactivity with AIDS-Related Non-Hodgkin Lymphoma. 61
31789046 2020
22
Role of Viral Infections in the Pathogenesis of Sjögren's Syndrome: Different Characteristics of Epstein-Barr Virus and HTLV-1. 61
32414149 2020
23
A pilot study to establish human T-cell leukemia virus type 1 (HTLV-1) carrier model using common marmoset (Callithrix jacchus). 61
31930552 2020
24
Prevalence of infectious diseases in patients with autoimmune blistering diseases. 61
32043652 2020
25
An RNA pseudoknot stimulates HTLV-1 pro-pol programmed -1 ribosomal frameshifting. 61
31980578 2020
26
Identifying the immune interactions underlying HLA class I disease associations. 61
32238263 2020
27
Effective Treatment with Tocilizumab in a Rheumatoid Arthritis Patient Complicated with Human T-cell Leukemia Virus Type 1-associated Myelopathy: A Case Report. 61
32321893 2020
28
Expression of TSLC1 in patients with HAM/TSP. 61
32285300 2020
29
First Description of Seronegative HTLV-1 Carriers in Argentina. 61
32043459 2020
30
Evaluation of artesunate for the treatment of adult T-cell leukemia/lymphoma. 61
31996318 2020
31
Relapsing Uveitis due to Human T-lymphotropic Virus Type 1 in a Patient Living With HIV Diagnosed by Metagenomic Deep Sequencing. 61
32206676 2020
32
Tackling HTLV-1 infection in ophthalmology: a nationwide survey of ophthalmic care in an endemic country, Japan. 61
32152142 2020
33
Molecular biology of human T cell leukemia virus. 61
31103249 2020
34
Proteomic profiling of HTLV-1 carriers and ATL patients reveals sTNFR2 as a novel diagnostic biomarker for acute ATL. 61
32196559 2020
35
Enhanced T-Cell Maturation and Monocyte Aggregation Are Features of Cellular Inflammation in Human T-Lymphotropic Virus Type 1-Associated Myelopathy. 61
31063543 2020
36
Cutaneous manifestations of adult T-cell leukemia/lymphoma. 61
31387753 2020
37
Epidemiology and survival trend of adult T-cell leukemia/lymphoma in the United States. 61
31769871 2020
38
Clinical significance of soluble CADM1 as a novel marker for adult T-cell leukemia/lymphoma. 61
32054656 2020
39
Cell death induced by dorsomorphin in adult T-cell leukemia/lymphoma is AMPK-independent. 61
32027454 2020
40
HTLV-1 bZIP factor: the key viral gene for pathogenesis. 61
31915026 2020
41
Epidemiology of HTLV-1 Infection and ATL in Japan: An Update. 61
32547527 2020
42
A Nationwide Antenatal Human T-Cell Leukemia Virus Type-1 Antibody Screening in Japan. 61
32328047 2020
43
Conservation of a Neutralization Epitope of Human T-cell Leukemia Virus Type 1 (HTLV-1) among Currently Endemic Clinical Isolates in Okinawa, Japan. 61
32012672 2020
44
Human T-cell leukemia virus type 1 may invalidate T-SPOT.TB assay results in rheumatoid arthritis patients: A retrospective case-control observational study. 61
32459801 2020
45
Association of TLR3 single nucleotide polymorphisms with susceptibility to HTLV-1 infection in Iranian asymptomatic blood donors. 61
32578708 2020
46
HTLV-1 Infection and Rheumatic Diseases. 61
32117170 2020
47
Uncommon Association Between Diabetic Ketoacidosis, Thyrotoxicosis, Cutaneous Abscess and Acute Pericarditis in an Immunocompetent Patient: A Single Case Report and Literature Review. 61
31654516 2020
48
The Role of Chemokines in the Pathogenesis of HTLV-1. 61
32231656 2020
49
HTLV-1 in Ophthalmology. 61
32218778 2020
50
Strategies of Human T-Cell Leukemia Virus Type 1 for Persistent Infection: Implications for Leukemogenesis of Adult T-Cell Leukemia-Lymphoma. 61
32508789 2020
Sources

Variations for Human T-Cell Leukemia Virus Type 1

About this section
Sources

Expression for Human T-Cell Leukemia Virus Type 1

About this section
Search GEO for disease gene expression data for Human T-Cell Leukemia Virus Type 1.
Sources

Pathways for Human T-Cell Leukemia Virus Type 1

About this section

Pathways related to Human T-Cell Leukemia Virus Type 1 according to GeneCards Suite gene sharing:

(show top 50) (show all 88)
# Super pathways Score Top Affiliating Genes
1
Toll-like Receptor Signaling Pathway 36 1
Show member pathways
 13.08 NFKB1 JUN EP300 CREBBP CREB1 CDKN1A
2
G-Beta Gamma Signaling 63
Show member pathways
 13.03 NFKB1 JUND JUN GLI2 EP300 CREBBP
3
PI3K-Akt signaling pathway 36
Show member pathways
 13.01 NFKB1 EP300 CRTC2 CREBBP CREB1 CDKN1A
4
Endometrial cancer 36
Show member pathways
 12.89 NFKB1 JUN EP300 CREBBP CREB1 CDKN1A
5
NFAT and Cardiac Hypertrophy 63
Show member pathways
 12.88 NFKB1 JUN EP300 CREBBP CREB1
6
Organelle biogenesis and maintenance 65
Show member pathways
 12.86 CRTC3 CRTC2 CRTC1 CREBBP CREB1
7
Pathways in cancer 36
12.85 NFKB1 JUN GLI2 EP300 CREBBP CDKN1A
8
Measles 36
Show member pathways
 12.84 NFKB1 JUN EP300 CREBBP CDKN1A
9
Common Cytokine Receptor Gamma-Chain Family Signaling Pathways 64
Show member pathways
 12.8 NFKB1 JUND JUN CREB1 CDKN1A
10
Relaxin signaling pathway 36
Show member pathways
 12.7 NFKB1 JUN EP300 CREBBP CREB1
11
nNOS Signaling in Skeletal Muscle 63
Show member pathways
 12.69 NFKB1 JUN EP300 CREBBP CREB1
12
4-1BB Pathway 63
Show member pathways
 12.66 NFKB1 JUN CREBBP CREB1
13
ErbB signaling pathway 36 1
Show member pathways
 12.64 NFKB1 JUN EP300 CREBBP CDKN1A
14
Human cytomegalovirus infection 36
Show member pathways
 12.61 NFKB1 JUN EP300 CREBBP CREB1 CDKN1A
15
Notch Signaling Pathway (WikiPathways) 1
Show member pathways
 12.56 NFKB1 EP300 CREBBP CDKN1A
16
MicroRNAs in cancer 36
12.54 NFKB1 EP300 CREBBP CDKN1A
17
Prolactin Signaling Pathway 36 1
Show member pathways
 12.51 NFKB1 JUN EP300 CREBBP CREB1
18
Development VEGF signaling via VEGFR2 - generic cascades 22
Show member pathways
 12.43 NFKB1 JUND JUN CREB1
19
Development IGF-1 receptor signaling 22
Show member pathways
 12.42 NFKB1 EP300 CREB1 CDKN1A
20
cAMP signaling pathway 36
12.36 NFKB1 JUN EP300 CREBBP CREB1
21
Translation Non-genomic (rapid) action of Androgen Receptor 22
Show member pathways
 12.34 NFKB1 GLI2 EP300 CDKN1A
22
Toll Comparative Pathway 63
Show member pathways
 12.34 NFKB1 JUND JUN EP300 CREB1
23
G-protein signaling Ras family GTPases in kinase cascades (scheme) 22
Show member pathways
 12.33 NFKB1 JUND JUN CREB1
25
Tuberculosis 36
12.27 NFKB1 EP300 CREBBP CREB1
26
C-type lectin receptor signaling pathway 36
Show member pathways
 12.23 NFKB1 JUND JUN EP300 CREBBP
27
Viral carcinogenesis 36
12.22 NFKB1 JUN EP300 CREBBP CREB1 CDKN1A
28
Integrated Breast Cancer Pathway 1
12.18 NFKB1 JUN EP300 CREB1
29
NGF Pathway 63
Show member pathways
 12.17 NFKB1 JUN CREBBP CREB1
30
Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways 1
12.17 NFKB1 JUN EP300 CREBBP CREB1
31
Brain-Derived Neurotrophic Factor (BDNF) signaling pathway 1
12.14 NFKB1 JUN CRTC1 CREB1
32
BMAL1-CLOCK,NPAS2 activates circadian gene expression 65
Show member pathways
 12.1 EP300 CRTC3 CRTC2 CRTC1 CREBBP CREB1
33
Direct p53 effectors 1
12.09 JUN EP300 CREBBP CDKN1A
34
FoxO signaling pathway 36
Show member pathways
 12.08 EP300 CREBBP CDKN1A
35
Osteoclast differentiation 36
12.08 NFKB1 JUND JUN CREB1
36
Mitochondrial Gene Expression 1
Show member pathways
 12.06 CRTC3 CRTC2 CRTC1 CREBBP CREB1
37
Pre-NOTCH Expression and Processing 65
Show member pathways
 12.04 JUN EP300 CREBBP
38
Development A2A receptor signaling 22
Show member pathways
 12.03 NFKB1 JUN CREB1
39
Ceramide Pathway 63
Show member pathways
 12.03 NFKB1 JUND JUN
40
TGF-beta Signaling Pathway (WikiPathways) 1
12.03 JUND JUN EP300 CREBBP CDKN1A
41
Amphetamine addiction 36
Show member pathways
 12.01 NFKB1 JUN CREB1
42
HIF-1 signaling pathway 36
12 NFKB1 EP300 CREBBP CDKN1A
43
DNA Damage Response (only ATM dependent) 1
11.99 NFKB1 JUN CDKN1A
44
TNF signaling pathway 36
11.98 NFKB1 JUN CREB1
45
Glucagon signaling pathway 36
11.98 EP300 CRTC2 CREBBP CREB1
46
Insulin resistance 36
Show member pathways
 11.97 NFKB1 CRTC2 CREB1
47
Long-term potentiation 36
Show member pathways
 11.97 EP300 CREBBP CREB1
48
Parathyroid hormone synthesis, secretion and action 36
11.95 JUND CREB1 CDKN1A
49
TGF-beta Signaling Pathways 64
11.92 NFKB1 JUND JUN CREB1
50
Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors 65
Show member pathways
 11.89 EP300 CREBBP CDKN1A
Sources

GO Terms for Human T-Cell Leukemia Virus Type 1

About this section

Cellular components related to Human T-Cell Leukemia Virus Type 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 10.1 RPL6 NFKB1 GLI2 EP300 CRTC3 CRTC2
2 nucleus GO:0005634 9.8 RPL6 NFKB1 JUND JUN GLI2 EP300
3 transcription factor complex GO:0005667 9.56 JUND JUN EP300 CREB1
4 nucleoplasm GO:0005654 9.44 NFKB1 JUND JUN GLI2 EP300 CRTC3
5 transcription factor AP-1 complex GO:0035976 9.16 JUND JUN

Biological processes related to Human T-Cell Leukemia Virus Type 1 according to GeneCards Suite gene sharing:

(show all 30)
# Name GO ID Score Top Affiliating Genes
1 regulation of transcription, DNA-templated GO:0006355 10.1 RPL6 NFKB1 JUND JUN EP300 CREBBP
2 negative regulation of transcription by RNA polymerase II GO:0000122 10 NFKB1 JUND JUN GLI2 EP300 CREBBP
3 response to drug GO:0042493 9.89 JUND JUN CREB1 CDKN1A
4 transcription by RNA polymerase II GO:0006366 9.85 NFKB1 JUND JUN CREB1
5 positive regulation of transcription, DNA-templated GO:0045893 9.85 NFKB1 JUN GLI2 EP300 CREBBP CREB1
6 response to organic cyclic compound GO:0014070 9.81 JUND JUN CDKN1A
7 viral process GO:0016032 9.8 EP300 CRTC3 CRTC2 CRTC1 CREBBP CREB1
8 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.78 NFKB1 EP300 CREBBP
9 regulation of cell cycle GO:0051726 9.76 JUND JUN EP300 CDKN1A
10 rhythmic process GO:0048511 9.73 EP300 CRTC1 CREBBP CREB1
11 response to cytokine GO:0034097 9.69 NFKB1 JUND JUN
12 protein homotetramerization GO:0051289 9.67 CRTC3 CRTC2 CRTC1
13 DNA demethylation GO:0080111 9.65 APOBEC3B APOBEC3A
14 positive regulation of type I interferon production GO:0032481 9.65 NFKB1 EP300 CREBBP
15 negative regulation of transposition GO:0010529 9.64 APOBEC3B APOBEC3A
16 osteoblast development GO:0002076 9.64 JUND GLI2
17 positive regulation of transcription of Notch receptor target GO:0007221 9.63 EP300 CREBBP
18 positive regulation by host of viral transcription GO:0043923 9.62 JUN EP300
19 negative regulation of single stranded viral RNA replication via double stranded DNA intermediate GO:0045869 9.62 APOBEC3B APOBEC3A
20 response to muscle stretch GO:0035994 9.61 NFKB1 JUN
21 protein acetylation GO:0006473 9.6 EP300 CREBBP
22 cellular response to stress GO:0033554 9.58 JUND JUN
23 cytidine to uridine editing GO:0016554 9.58 APOBEC3B APOBEC3A
24 cytidine deamination GO:0009972 9.57 APOBEC3B APOBEC3A
25 response to organic substance GO:0010033 9.56 JUND JUN CREB1 CDKN1A
26 DNA cytosine deamination GO:0070383 9.54 APOBEC3B APOBEC3A
27 circadian rhythm GO:0007623 9.46 JUND JUN EP300 CREB1
28 N-terminal peptidyl-lysine acetylation GO:0018076 9.4 EP300 CREBBP
29 positive regulation of transcription by RNA polymerase II GO:0045944 9.32 NFKB1 JUND JUN GLI2 EP300 CRTC3
30 positive regulation of CREB transcription factor activity GO:0032793 9.13 CRTC3 CRTC2 CRTC1

Molecular functions related to Human T-Cell Leukemia Virus Type 1 according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.27 RPL6 NFKB1 JUND JUN GLI2 EP300
2 sequence-specific DNA binding GO:0043565 9.95 NFKB1 JUND JUN GLI2 CREB1
3 RNA polymerase II regulatory region sequence-specific DNA binding GO:0000977 9.88 NFKB1 GLI2 EP300 CREB1
4 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 9.88 NFKB1 JUND JUN GLI2 EP300 CREB1
5 DNA-binding transcription activator activity, RNA polymerase II-specific GO:0001228 9.83 NFKB1 JUND JUN GLI2 CREB1
6 transcription coactivator activity GO:0003713 9.81 JUND JUN EP300 CREBBP
7 double-stranded DNA binding GO:0003690 9.73 JUND JUN CREB1
8 chromatin binding GO:0003682 9.73 NFKB1 JUN GLI2 EP300 CRTC2 CREBBP
9 transcription regulatory region DNA binding GO:0044212 9.72 NFKB1 JUND JUN GLI2 CREB1
10 transcription coregulator activity GO:0003712 9.71 EP300 CREBBP CREB1
11 acetyltransferase activity GO:0016407 9.57 EP300 CREBBP
12 cAMP response element binding GO:0035497 9.52 JUN CREB1
13 cytidine deaminase activity GO:0004126 9.49 APOBEC3B APOBEC3A
14 deoxycytidine deaminase activity GO:0047844 9.48 APOBEC3B APOBEC3A
15 peptide-lysine-N-acetyltransferase activity GO:0061733 9.46 EP300 CREBBP
16 RNA polymerase II activating transcription factor binding GO:0001102 9.46 JUN EP300 CREBBP CREB1
17 transcription factor binding GO:0008134 9.17 NFKB1 JUND JUN GLI2 EP300 CREBBP
18 cAMP response element binding protein binding GO:0008140 9.13 CRTC3 CRTC2 CRTC1
Sources

Sources for Human T-Cell Leukemia Virus Type 1

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....